Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.
暂无分享,去创建一个
B. Murphy | J. Blaney | Joseph E Blaney | Christopher T Hanson | Brian R Murphy | Daniel H. Johnson | Daniel H Johnson | Gracielle G Manipon | Cai-Yen Firestone | Stephen S Whitehead | C. Hanson | C. Firestone | S. Whitehead | G. G. Manipon
[1] A. Nisalak,et al. A prospective study of dengue infections in Bangkok. , 1988, The American journal of tropical medicine and hygiene.
[2] M. St. Claire,et al. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. , 1999, Virology.
[3] A. Pletnev. Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice. , 2001, Virology.
[4] A. Davidson,et al. Mutagenesis of the Dengue Virus Type 2 NS3 Protein within and outside Helicase Motifs: Effects on Enzyme Activity and Virus Replication , 2001, Journal of Virology.
[5] C. Huang,et al. Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine , 2000, Journal of Virology.
[6] R. Karron,et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. , 2001, The American journal of tropical medicine and hygiene.
[7] M. Bray,et al. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[8] D. Mosier,et al. Human xenograft models for virus infection. , 2000, Virology.
[9] J. An,et al. Development of a novel mouse model for dengue virus infection. , 1999, Virology.
[10] F. Guirakhoo,et al. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.
[11] A. Patwari,et al. Hepatic dysfunction in childhood dengue infection. , 2000, Journal of tropical pediatrics.
[12] E. Holmes,et al. Secondary structure of the 3' untranslated region of flaviviruses: similarities and differences. , 1997, Nucleic acids research.
[13] D. Vaughn,et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. , 1994, The Journal of infectious diseases.
[14] A. Barrett,et al. Genetic variation in the 3' non-coding region of dengue viruses. , 2001, Virology.
[15] A. Mazzei. Molecular biology of dengue virus , 1998 .
[16] R. Chanock,et al. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys , 1996, Journal of virology.
[17] G. Kadaré,et al. Virus-encoded RNA helicases , 1997, Journal of virology.
[18] S. Wahid,et al. A comparison of the pattern of liver involvement in dengue hemorrhagic fever with classic dengue fever. , 2000, The Southeast Asian journal of tropical medicine and public health.
[19] W. Bancroft,et al. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. , 1984, The American journal of tropical medicine and hygiene.
[20] F. Guirakhoo,et al. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates , 2000, Journal of Virology.
[21] D. Vaughn,et al. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[22] A. Pletnev,et al. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] L. Rosen,et al. Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. , 1999, The American journal of tropical medicine and hygiene.
[24] Duane J. Gubler,et al. Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.
[25] P. Marianneau,et al. Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. , 1999, Human pathology.
[26] P. Young,et al. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. , 1996, Virology.
[27] A. Pletnev,et al. Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome. , 1995, Virology.
[28] A. Allison,et al. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection , 1977, The Journal of experimental medicine.
[29] T. Yamane,et al. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. , 1982, Cancer research.
[30] M. Aye,et al. Risk factors in dengue shock syndrome. , 1997, The American journal of tropical medicine and hygiene.
[31] R. Chanock,et al. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. , 1994, Vaccine.
[32] D. Vaughn,et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. , 1996, Vaccine.
[33] C. King,et al. Study of Dengue Virus Infection in SCID Mice Engrafted with Human K562 Cells , 1998, Journal of Virology.
[34] D. Stone,et al. The 5' noncoding region and virulence of poliovirus vaccine strains. , 1994, Trends in microbiology.
[35] Peter F. Stadler,et al. Spontaneous and Engineered Deletions in the 3′ Noncoding Region of Tick-Borne Encephalitis Virus: Construction of Highly Attenuated Mutants of a Flavivirus , 1998, Journal of Virology.
[36] F. Murphy,et al. Immunization against Viral Diseases , 1968 .
[37] S. Watowich,et al. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. , 1999, Virology.
[38] A. Nisalak,et al. Early clinical and laboratory indicators of acute dengue illness. , 1997, The Journal of infectious diseases.
[39] J. S. Porterfield. Exotic Viral Infections , 1998, Nature Medicine.
[40] B. Murphy,et al. Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes , 2002, Journal of Virology.
[41] R. Padmanabhan,et al. The Serine Protease and RNA-Stimulated Nucleoside Triphosphatase and RNA Helicase Functional Domains of Dengue Virus Type 2 NS3 Converge within a Region of 20 Amino Acids , 1999, Journal of Virology.
[42] C. Rice,et al. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation , 1997, Journal of virology.
[43] P. Marianneau,et al. Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children , 2001, Virchows Archiv.
[44] D. L. Harris,et al. Partial purification and characterization of a dengue virus soluble complement-fixing antigen. , 1970, Journal of immunology.
[45] W. Bancroft,et al. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. , 1987, The American journal of tropical medicine and hygiene.
[46] D. Vaughn,et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.
[47] J P Griffith,et al. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. , 1998, Structure.
[48] W. Bancroft,et al. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. , 1984, The Journal of infectious diseases.
[49] B. Murphy,et al. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. , 1998, Virology.
[50] Y. Liaw,et al. Liver biochemical tests and dengue fever. , 1992, The American journal of tropical medicine and hygiene.
[51] Takemoto Kk. Plaque mutants of animal viruses. , 1966 .
[52] P. Russell,et al. Dengue-2 vaccine: preparation from a small-plaque virus clone , 1980, Infection and immunity.
[53] M. Bray,et al. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[54] B. Murphy,et al. Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice , 2001, Journal of Virology.
[55] C. Mandl,et al. Adaptation of Tick-Borne Encephalitis Virus to BHK-21 Cells Results in the Formation of Multiple Heparan Sulfate Binding Sites in the Envelope Protein and Attenuation In Vivo , 2001, Journal of Virology.
[56] W. Bancroft,et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. , 1988, The Journal of infectious diseases.
[57] R. Chanock,et al. The nucleotide sequence of dengue type 4 virus: analysis of genes coding for nonstructural proteins. , 1987, Virology.
[58] R. Chanock,et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. , 1994, Vaccine.
[59] N. Bhamarapravati,et al. Live attenuated tetravalent dengue vaccine. , 2000, Vaccine.
[60] D. Gubler,et al. Impact of dengue/dengue hemorrhagic fever on the developing world. , 1999, Advances in virus research.
[61] D. Vaughn,et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. , 2001, Vaccine.
[62] C. Huang,et al. Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5′ Noncoding Region and Nonstructural Proteins 1 and 3 , 2000, Journal of Virology.
[63] E. Koonin,et al. A new superfamily of putative NTP‐binding domains encoded by genomes of small DNA and RNA viruses , 1990, FEBS letters.